Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
ARVINAS, INC. | Director | Common Stock | 14.1K | $665K | $47.05 | May 29, 2024 | Direct |
ARVINAS, INC. | Director | Stock Option (right to buy) | 9.07K | $145K | $16.00 | May 29, 2024 | Direct |
Sana Biotechnology, Inc. | EVP, Head of Development & CMO | Stock Options (Right to Buy) | 250K | Mar 3, 2022 | Direct | ||
Astria Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 28.2K | Apr 8, 2024 | Direct | ||
Calithera Biosciences, Inc. | Director | Stock Option (Right to Buy) | 20K | Jun 1, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ARVN | ARVINAS, INC. | May 29, 2024 | 2 | $0 | 4 | May 31, 2024 | Director |
ATXS | Astria Therapeutics, Inc. | Apr 8, 2024 | 1 | $0 | 4 | Apr 9, 2024 | Director |
ATXS | Astria Therapeutics, Inc. | Apr 5, 2024 | 0 | $0 | 3 | Apr 9, 2024 | Director |
ARVN | ARVINAS, INC. | Jun 15, 2023 | 2 | $0 | 4 | Jun 20, 2023 | Director |
ARVN | ARVINAS, INC. | Jun 15, 2023 | 0 | $0 | 3 | Jun 20, 2023 | Director |
CALA | Calithera Biosciences, Inc. | Jun 1, 2022 | 1 | $0 | 4 | Jun 3, 2022 | Director |
SANA | Sana Biotechnology, Inc. | Mar 3, 2022 | 1 | $0 | 4 | Mar 8, 2022 | EVP, Head of Development & CMO |
SANA | Sana Biotechnology, Inc. | Sep 15, 2021 | 2 | -$1.56M | 4 | Sep 17, 2021 | EVP, Head of Development & CMO |
CALA | Calithera Biosciences, Inc. | Jun 11, 2021 | 1 | $0 | 4 | Jun 14, 2021 | Director |